Effects of haloperidol and clozapine administration on oxidative stress in rat brain, liver and serum

Neuroscience Letters

Volumn 591, Issue , 2015, Pages 36-40

  Andreazza, Ana C ^a,b   Barakauskas, Vilte E ^a   Fazeli, Salar ^a   Feresten, Abigail ^a   Shao, Li ^a   Wei, Vivien ^a   Wu, Che Hsuan ^a   Barr, Alasdair M ^a   Beasley, Clare L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Antioxidant; Antipsychotic agent; Lipid peroxidation; Peroxiredoxin; Schizophrenia

Indexed keywords

CLOZAPINE; HALOPERIDOL; PEROXIREDOXIN 2; PEROXIREDOXIN 6; NEUROLEPTIC AGENT; PEROXIREDOXIN;

ADULT; ANIMAL EXPERIMENT; ARTICLE; BRAIN; CONTROLLED STUDY; GRAY MATTER; LIPID PEROXIDATION; LIVER; MALE; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN OXIDATION; RAT; SERUM; WHITE MATTER; ANIMAL; ANTIBODY SPECIFICITY; DRUG EFFECTS; METABOLISM; OXIDATION REDUCTION REACTION; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; CLOZAPINE; HALOPERIDOL; LIPID PEROXIDATION; LIVER; MALE; ORGAN SPECIFICITY; OXIDATION-REDUCTION; OXIDATIVE STRESS; PEROXIREDOXINS; RATS, SPRAGUE-DAWLEY; SERUM;

EID: 84922962770     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2015.02.028     Document Type: Article

References (47)

1. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
2. Chadda R.K., Ramshankar P., Deb K.S., Sood M. Metabolic syndrome in schizophrenia: differences between antipsychotic-naïve and treated patients. J. Pharmacol. Pharmacother. 2013, 4:176-186.
3. Nielsen J., Correll C.U., Manu P., Kane J.M. Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?. J. Clin. Psychiatry 2013, 74:603-613.
4. Ando K., Fujita T. Metabolic syndrome and oxidative stress. Free Radical Biol. Med. 2009, 47:213-218.
5. Fischer V., Haar J.A., Greiner L., Lloyd R.V., Mason R.P. Possible role of free radical formation in clozapine (clozaril)-induced agranulocytosis. Mol. Pharmacol. 1991, 40:846-853.
6. Cadet J.L., Lohr J.B. Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E. Ann. N. Y. Acad. Sci. 1989, 570:176-185.
7. Friedman J. Why is the nervous system vulnerable to oxidative stress?. Oxidative Stress and Free Radical Damage in Neurology 2011, 19-27. Humana Press. N. Gadoth, H.H. Gobel (Eds.).
8. Flatow J., Buckley P., Miller B.J. Meta-analysis of oxidative stress in schizophrenia. Biol. Psychiatry 2013, 74:400-409.
9. O'Donnell P. Cortical interneurons: immune factors and oxidative stress as early targets for schizophrenia. Eur. J. Neurosci. 2012, 35:1866-1870.
10. Wang J.F., Shao L., Sun X., Young L.T. Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord. 2009, 11:523-529.
11. Martins M.R., Petronilho F.C., Gomes K.M., Dal-Pizzol F., Streck E.L., Quevedo J. Antipsychotic-induced oxidative stress in rat brain. Neurotox. Res. 2008, 13:63-69.
12. Polydoro M., Schröder N., Lima M.N., Caldana F., Laranja D.C., Bromberg E., Roesler R., Quevedo J., Moreira J.C., Dal-Pizzol F. Haloperidol- and clozapine-induced oxidative stress in the rat brain. Pharmacol. Biochem. Behav. 2004, 78:751-756.
13. Reinke A., Martins M.R., Lima M.S., Moreira J.C., Dal-Pizzol F., Quevedo J. Haloperidol and clozapine but not olanzapine, induced oxidative stress in rat brain. Neurosci. Lett. 2004, 372:157-160.
14. Parikh V., Khan M.M., Mahadik S.P. Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J. Psychiatr. Res. 2003, 37:43-51.
15. Pillai A., Parikh V., Terry A.V., Mahadik S.P. Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J. Psychiatr. Res. 2007, 41:372-386.
16. Naidu P.S., Singh A., Kulkarni S.K. Reversal of haloperidol-induced orofacial dyskinesia by quercetin: a bioflavonoid. Psychopharmacology (Berl.) 2003, 167:418-423.
17. Burger M.E., Fachinetto R., Zeni G., Rocha J.B. Ebselen attenuates haloperidol-induced orofacial dyskinesia and oxidative stress in rat brain. Pharmacol. Biochem. Behav. 2005, 81:608-615.
18. Bishnoi M., Chopra K., Kulkarni S.K. Modulatory effect of neurosteroids in haloperidol-induced vacuous chewing movements and related behaviors. Psychopharmacology (Berl.) 2008, 196:243-254.
19. Pennington K., Beasley C.L., Dicker P., Fagan A., English J., Pariante C.M., Wait R., Dunn M.J., Cotter D.R. Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. Mol. Psychiatry 2008, 13:1102-1117.
20. Martins-de-Souza D., Gattaz W.F., Schmitt A., Novello J.C., Marangoni S., Turck C.W., Dias-Neto E. Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation. BMC Psychiatry 2009, 9:17.
21. Prabakaran S., Swatton J.E., Ryan M.M., Huffaker S.J., Huang J.T., Griffin J.L., Wayland M., Freeman T., Dudbridge F., Lilley K.S., Karp N.A., Hester S., Tkachev D., Mimmack M.L., Yolken R.H., Webster M.J., Torrey E.F., Bahn S. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatry 2004, 9:684-697.
22. Keane S., Lane A., Larkin T., Clarke M. Management of clozapine-related hepatotoxicity. J. Clin. Psychopharmacol. 2009, 29:606-607.
23. Barakauskas V.E., Ypsilanti A.R., Barr A.M., Innis S.M., Honer W.G., Beasley C.L. Effects of sub-chronic clozapine and haloperidol administration on brain lipid levels. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34:669-673.
24. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1986, Academic Press, New York. 2nd ed.
25. Feresten A.H., Barakauskas V., Ypsilanti A., Barr A.M., Beasley C.L. Increased expression of glial fibrillary acidic protein in prefrontal cortex in psychotic illness. Schizophr. Res. 2013, 150:252-257.
26. Abdel-Salam O.M., Youness E.R., Khadrawy Y.A., Sleem A.A. Brain and liver oxidative stress after sertraline and haloperidol treatment in mice. J. Basic Clin. Physiol. Pharmacol. 2013, 25:1-9.
27. De Hert M., Detraux J., van Winkel R., Yu W., Correll C.U. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat. Rev. Endocrinol. 2011, 8:114-126.
28. Boyda H.N., Procyshyn R.M., Tse L., Hawkes E., Jin C.H., Pang C.C., Honer W.G., Barr A.M. Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats. J. Psychiatry Neurosci. 2012, 37:407-415.
29. Boyda H.N., Tse L., Procyshyn R.M., Wong D., Wu T.K., Pang C.C., Barr A.M. A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34:945-954.
30. Wiernsperger N. Hepatic function and the cardiometabolic syndrome. Diabetes Metab. Syndr. Obes. 2013, 6:379-388.
31. Hummer M., Kurz M., Kurzthaler I., Oberbauer H., Miller C., Fleischhacker W.W. Hepatotoxicity of clozapine. J. Clin. Psychopharmacol. 1997, 117:314-317.
32. Dietrich-Muszalska A., Olas B. Isoprostenes as indicators of oxidative stress in schizophrenia. World J. Biol. Psychiatry 2009, 10:27-33.
33. Kunz M., Gama C.S., Andreazza A.C., Salvador M., Ceresér K.M., Gomes F.A., Belmonte-de-Abreu P.S., Berk M., Kapczinski F. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1677-1681.
34. Zhang X.Y., Tan Y.L., Cao L.Y., Wu G.Y., Xu Q., Shen Y., Zhou D.F. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr. Res. 2006, 81:291-300.
35. Mahadik S.P., Mukherjee S., Scheffer R., Correnti E.E., Mahadik J.S. Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biol. Psychiatry 1998, 43:674-679.
36. Ramos-Loyo J., Medina-Hernández V., Estarrón-Espinosa M., Canales-Aguirre A., Gómez-Pinedo U., Cerdán-Sánchez L.F. Sex differences in lipid peroxidation and fatty acid levels in recent onset schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 44:154-161.
37. Dietrich-Muszalska A., Kopka J., Kwiatkowska A. The effects of ziprasidone: clozapine and haloperidol on lipid peroxidation in human plasma (in vitro): comparison. Neurochem. Res. 2013, 38:1490-1495.
38. Meyer J.M., Koro C.E. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr. Res. 2004, 70:1-17.
39. Rhee S.G., Woo H.A., Kil I.S., Bae S.H. Peroxiredoxin functions as a peroxidase and a regulator and sensor of local peroxides. J. Biol. Chem. 2012, 287:4403-4410.
40. Manevich Y., Hutchens S., Halushka P.V., Tew K.D., Townsend D.M., Jauch E.C., Borg K. Peroxiredoxin VI oxidation in cerebrospinal fluid correlates with traumatic brain injury outcome. Free Radical Biol. Med. 2014, 72:210-221.
41. Gan Y., Ji X., Hu X., Luo Y., Zhang L., Li P., Liu X., Yan F., Vosler P., Gao Y., Stetler R.A., Chen J. Transgenic overexpression of peroxiredoxin-2 attenuates ischemic neuronal injury via suppression of a redox-sensitive pro-death signaling pathway. Antioxid. Redox Signal. 2012, 17:719-732.
42. Kapur S., VanderSpek S.C., Brownlee B.A., Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J. Pharmacol. Exp. Ther. 2003, 305:625-631.
43. Quinn R. Comparing rat's to human's age: how old is my rat in people years?. Nutrition 2005, 21:775-777.
44. Dorph-Petersen K.A., Pierri J.N., Perel J.M., Sun Z., Sampson A.R., Lewis D.A. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology 2005, 30:1649-1661.
45. Vernon A.C., Natesan S., Modo M., Kapur S. Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation. Biol. Psychiatry 2011, 69:936-944.
46. Vernon A.C., Crum W.R., Lerch J.P., Chege W., Natesan S., Modo M., Cooper J.D., Williams S.C., Kapur S. Reduced cortical volume and elevated astrocyte density in rats chronically treated with antipsychotic drugs-linking magnetic resonance imaging findings to cellular pathology. Biol. Psychiatry 2014, 75:982-990.
47. Yao J.K., Reddy R. Oxidative stress in schizophrenia: pathogenetic and therapeutic implications. Antioxid. Redox Signal. 2011, 15:1999-2002.